340B Exemptions Offer Manufacturers ‘Significant’ Incentives To Seek Orphan Status – HHS OIG
Office of Inspector General report explores the orphan drug status of a set of blockbuster drugs with the highest level of spending in Medicare.
You may also be interested in...
Focusing on orphan-first drugs may be best route to address pricing concerns, Health Affairs study suggests after finding that just one-fifth of spending on 15 top-selling partial orphan drugs was for the drugs’ rare disease indications.
Biogen suggests potential precedents in past coverage decisions for upcoming Medicare determination on Aduhelm and other amyloid-directed monoclonal antibodies during earnings call.
First interchangeable insulin biosimilar gains preferred status on one of the largest national formularies in the US.